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KNOOK, A. HOFMAN AND J. VIJG. Decreased DNA repair capacity in familial, but not in sporadic Alzheimer's disease. 
NEUROBIOL AGING 12(4) 367-370, 1991 .--Using the alkaline filter elution technique we determined the induction and disap- 
pearance of DNA single-strand breaks (SSB) in freshly isolated peripheral blood lymphocytes (PBL) from 43 Alzheimer's disease 
(AD) patients and 48 normal, healthy age- and sex-matched control subjects following in vitro exposure to N-ethyl-N-nitrosourea 
(ENU). The mean percentage SSB disappearance in PBL from control subjects at 1 h after ENU treatment was 41.4 _+ 2.9%; this 
was not significantly different from that found in samples from AD patients which had no (n = 16) or one (n = 12) first-degree 
relative with dementia (42.5___ 8.2% and 43.0_4.4%, respectively; p>0.75). However, in PBL of 15 AD patients with at least 
two first-degree relatives with dementia the mean percentage SSB disappearance was 23.6 ___ 5.8%, which was significantly lower 
than that found in controls (p<0.01) or in the other AD patients (p<0,02). 
Alzheimer DNA repair Ethylnitrosourea Lymphocytes Alkaline elution 
ALZHEIMER'S disease (AD) is a common neurodegenerative 
disorder characterized by the premature death of neurons (9). It 
has been found that AD patient-derived fibroblast and lympho- 
blastoid cell lines have an increased sensitivity to the cell killing 
effects of alkylating agents and X-rays, as compared to cell lines 
from normal age-matched controls (17, 18, 20). This phenome- 
non has been attributed to some defect in the capacity to remove 
brain-specific DNA damages (17-19). Thus in vitro expression 
of such a defect, i.e., cell death, in cells other than brain cells 
will become apparent after exposure to certain DNA-damaging 
agents, but in vivo the defect will be prominent only in the neu- 
ronal cells of AD patients (17). Indeed, direct comparison of 
DNA-damage levels in neuronal tissue of AD patients and con- 
trois indicated an at least two-fold higher level of DNA breaks 
in cortex of AD patients as compared to controls (15). 
In keeping with the observations mentioned above, decreased 
levels of DNA repair in fibroblast and lymphoid cell lines of 
AD patients after treatment with methyl methanesulfonate or 
N-methyl-N'-nitro-N-nitrosoguanidine hav  been found (3, 8, 
13, 19), although some of these results have been challenged 
(10,11). Thus far, DNA repair determinations have not been 
made on freshly isolated cells from AD patients. Such direct- 
testing for general DNA repair defects would circumvent arte- 
facts that are associated with the use of cell lines and may offer 
new diagnostic riteria. 
In this study a highly sensitive alkaline filter elution assay 
was used to determine the induction and disappearance of SSB 
in peripheral blood lymphocytes (PBL) of AD patients and nor- 
mal age-matched controls exposed to N-ethyl-N-nitrosourea (ENU). 
We found that in PBL from sporadic AD patients with no or 
only one first-degree relative with dementia (n= 16 and n= 12, 
respectively) and in PBL of 48 age-matched controls the mean 
percentage SSB disappearance was about 40%, whereas in PBL 
from 15 AD patients with at least 2 first-degree relatives the 
mean percentage SSB disappearance of about 23% was signifi- 
cantly lower as compared to the former two groups. 
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METHOD 
Selection of Patients and Control Subjects 
Patients and age-matched controls were participants in an on- 
going epidemiological study of risk factors of clinically diag- 
nosed AD at the Department of Epidemiology and Biostatistics, 
Erasmus University Medical School (6). All patients with AD 
were selected according to the criteria established by the NIN- 
CDS-ADRDA (14). Systemic disorders or brain diseases other 
than AD, such as multi-infarct dementia, and dementia second- 
ary to alcoholism, depression, metabolic disorders, epilepsy, 
Parkinson's disease and other conditions were excluded using a 
clinical history, neurological examination and neuropsychologi- 
cal and laboratory tests (7). All patients fulfilled the following 
criteria: 1) slow progressive decline of intellectual function; 2) a 
score on the Clinical Dementia Rating scale of more than 0.5 
(7); 3) a score on the Short Portable Mental Status Question- 
naire (SPMSQ) of less than 20 (16); 4) a score of 7 or less on 
the Hachinski-scale (5); 5) no evidence for abnormalities on CT- 
scan other than cerebral atrophy; and 6) no evidence for focal 
dysfunction in the EEG. Full pedigree information was obtained 
by a structured interview of the next of kin of the patient or 
control (6). Patients and controls were classified according to the 
number of affected relatives. Patients were considered familial if 
there were 2 or more individuals known in their family with 
clinically diagnosed AD. Within the family of those patients, the 
disease was apparently inherited as an autosomal dominant dis- 
order. Using a breakpoint of 58 years in order to distinguish be- 
tween the early and late onset type of familial AD (4), all 
familial AD patients in the present study are classified as be- 
longing to late-onset families. AD patients and control subjects 
were similar with respect o age range (51-81 and 50-79 years, 
respectively). 
Lymphocyte Isolation and Treatment 
Informed consent was obtained from the responsible family 
members of the subjects with AD and/or directly from the con- 
trol subjects. Lymphocytes were isolated from 10 ml of coded 
blood samples, using Ficoll-Paque (Pharmacia) gradients (2), 
and washed twice in RPMI 1640 medium (Flow Laboratories) 
plus 2% fetal calf serum (FCS). All steps were performed at 
4°C. Viability of recovered PBL was always higher than 95% as 
measured by trypan blue dye exclusion. ENU (Sigma) was dis- 
solved in dimethylsulfoxide (DMSO) immediately before use. A 
constant number of ceils (3 × 106/ml) was used for each treat- 
ment in order to exclude variations in the amount of damage 
initially induced. Lymphocyte suspensions were exposed to 0.5 
mM ENU for 20 min in RPMI 1640 medium plus 20 mM 
Hepes, 2 mM glutamine and 5% FCS at 37°C. The DMSO con- 
centration during ENU exposure was never higher than 1%. 
Control cells were treated with RPMI containing the same DMSO 
concentration. At the end of the exposure period, cells were 
centrifuged and resuspended in RPMI 1640 supplemented with 
10% FCS and glutamine and incubated for repair at 37°C. For 
treatment with 4 Gy of 6°Co-~/-rays, PBL were suspended in 
RPMI 1640 medium plus 20 mM Hepes, 2 mM glutamine and 
5% FCS and irradiated on ice in a Gamma-ceU 100 (Atomic En- 
ergy of Canada Ltd.) at a dose rate of 6 Gy/min. After irradia- 
tion the cells were centrifuged and resuspended in RPMI 1640, 
10% FCS, 2 mM glutamine for repair incubation. 
Alkaline Filter Elution Assay 
The technique of alkaline filter elution (12), modified for an- 
alyzing nonradioactively abelled cells (21), was used to mea- 
sure ENU-induced DNA lesions, detected as single-strand breaks 
(SSB). In brief, cells were collected, centrifuged and resus- 
pended in ice-cold PBS (8.1 nflVl Na2HPO 4. 15 mM KHePO4, 
0.14 M NaC1 and 2.6 mM KCI) at a final concentration of 
1.5 × 10 6 cells/ml; 0.8 x 10 6 cells were applied per filter. Load- 
ing and lysing of the cells, as well as the elution of the DNA, 
were performed under subdued lighting in order to minimize ar- 
tificial induction of SSB. Elution was carried out at a flow rate 
of 0.03 ml/min. Six fractions were collected at 2.5 h intervals. 
After the addition of Hoechst 33258, DNA in each fraction was 
quantitated spectrofluorometrically, as described (15). All deter- 
minations and subsequent calculations of the percentage SSB 
disappearance were performed in a blinded manner. The elution 
results were plotted as the log percent of DNA remaining on the 
filter as a function of elution time. Linear regression between 
the data points obtained at t=2V2 and t= 12v2 h of elution time 
was used to determine the slope of the elution curves. Mean 
slopes of elution curves were used to calculate the percentage 
SSB disappearance. In all experiments, mean slopes were based 
on at least triplicate determinations and standardized with refer- 
ence to mean slopes of untreated control cells assayed in the 
same experiment. Variation between the triplicate determinations 
of a single sample was typically less than 2/~ 
RESULTS 
Table 1 shows the general characteristics of both the AD and 
control group. There were no significant differences in the mean 
age between AD patients and control subjects. Table 1 shows 
that 12 out of 43 AD patients (28%) had one first-degree rela- 
tive with dementia, as compared to 13 out of 48 controls (27%). 
Fifteen of the 43 AD patients (35%) and none of the controls 
had at least 2 first-degree relatives with dementia. These 15 fa- 
milial AD patients were not related in first, second or third 
degree. 
In a previous study on DNA repair in PBL from normal hu- 
man individuals we used the alkylating agent ENU at a dose of 
0.5 mM, which induces approximately 4000 SSB per cell and 
has no significant effect on cell survival ~1 ~. In that previous 
study we demonstrated that PBL from about 10% of normal 
young subjects suffer from a low capacity to remove ENU-in- 
duced SSB. The low level of repair appeared to correlate with a 
low level of survival of these cells at ENU doses of 1. 2 and 5 
mM (1). Figure 1 shows representative elution curves for PBL 
from a normal control subject and for PBL from a sporadic and 
a familial AD patient, directly after exposure to 0.5 mM ENU 
and after a 1 h repair incubation. The initial amount of SSB in 
PBL from these three selected subjects is not different. How- 
ever, following a 1 h repair incubation the amount of SSB was 
significantly decreased in PBL from the control subject and the 
sporadic AD patient, whereas PBL from the selected familial AD 
patient appeared incapable of removing the ENU-induced SSB 
(Fig. l, panels A-C). For PBL from these same individuals 
~/-ray-induced SSB were removed efficiently; repair was 
virtually complete within 1 h of repair incubation (Fig. 1. pan- 
els D-F). 
For 48 normal controls the percentage SSB disappearance 
was 41.4% - 2.9% (mean-+ SEM) which was not significantly 
different from the 36.1_+4.0% found in 43 AD patients Cp> 
0.75; Table 1). AD patients which had no or only one first-de- 
gree relative with dementia (sporadic AD) had a mean percent- 
age of SSB disappearance of 42.5%_+8.2% and 43.0%_+4.4%. 
respectively, which was not significantly different from that 
found in the control subjects (Table 1). However. AD patients 
with at least two first-degree relatives with dementia (considered 
as familial AD), had a significantly lower percentage SSB dis- 
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TABLE 1 
ENU-INDUCED SSB DISAPPEARANCE IN PBL FROM AD PATIENTS AND MATCHED CONTROL SUBJECTS 
SSB Induction+ 
Number of First-Degree 
Subjects Relatives With Dementia Number Age (years)* Female (%) t=0 t= 1 ENU Repair (%)~/ 
Controls 0 35 68.2 _ 1.15 72 0.181 +__ 0.01l 0.096 _+ 0.007 40.8 _+ 3.4 
1 13 70.0 *- 1.55 70 0.173 _ 0.013 0.100 +_. 0.012 44.3 +__ 5.5 
48 68.9 ± 0.93 71 0.179 ± 0.009 0.097 _+ 0.006 41.4 ± 2.9 
ADpatients 0 16 67.1 ~ 1.47 "s 88 0.164 + 0.011 "~ 0.084 _+ 0.009 "~ 42.5 +_+_ 8.2"' 
1 12 69.3 - 0.82 "s 83 0.180 ___ 0.011 "~ 0.101 +__ 0.009 ns 43.0 _+ 4.4 "* 
2 15 68.8 + 1.74 ~ 75 0.181 _+ 0.017 "~ 0.131 _+ 0.011§ 23.6 ___ 5.84! 
43 68 .3  -±- 0 .84  ~ 81 0 .176  -+- 0 .008  n~ 0 .105  + 0 .006  ~ 36.1 +_ 4 .0  "~ 
*Mean +- SEM. qNumber of SSB represented by the slope of the elution curve (mean +_ SEM) at the indicated times (in h) after the 20 min ENU 
treatment. ~:Percentages are the mean (--_ SEM) of the repair values as calculated for each individual subject. ~SNot significantly different from the 48 
control subjects. §Significantly different from the 48 control subjects (p<0.01, two-sided t-test) ¶Significantly different from the 48 control subjects 
(p<0.01) and the AD patients with 0 or 1 first-degree relative with dementia (p<0.02). 
appearance (23.6%---5.8%) than controls (p<0.01) or AD pa- 
tients with no or only one first-degree relative with dementia 
(p<0.02; Table 1). In PBL from six familial AD patients that 
were checked at 2.5 h posttreatment the percentage ENU-in- 
duced SSB disappearance was 34 .9%-  6,7% indicating that the 
rate rather than the total amount of repair was lower in PBL 
from familial AD patients (results not shown). A similar de- 
creased rate of SSB disappearance in PBL from some normal 
young subjects exposed in vitro to ENU was reported in our 
previous study (1). 
There was no statistically significant correlation between age 
and the percentage SSB disappearance at 1 h after exposure to 
ENU for either the AD groups, the control groups, or all groups 
combined. The amount of SSB disappearance was not associ- 
ated with the age of onset, the degree or the duration of the dis- 
ease. Also, no differences were observed between males and 
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FIG. 1. Representative elution curves of PBL from a normal control 
subject (A and D), a sporadic AD patient (B and E) and a familial AD 
patient (C and F) exposed in vitro to 0.5 mM ENU for 20 min at 37°C 
(A, B and C) or irradiated with 4 Gy of ",/-rays at 4°C (D, E and F). 
Untreated control cells (4); treated PBL, no repair incubation ( I ) ;  
treated cells, 1 h repair incubation (C)). 
females of either group (results not shown). 
DISCUSSION 
A deficiency in the ability of cells to repair alkylating agent- 
induced SSB could reflect a hypersensitivity o one or more spe- 
cific DNA lesions induced by those agents. The initial observations 
by Robbins et al. (17,18) and Scudiero et al. (20) of a signifi- 
cantly lower survival of fibroblast and lymphoid cell lines from 
AD patients appeared to be confirmed by recent reports of DNA 
repair deficiencies in AD cell lines treated with methyl methane- 
sulfonate (MMS) or N-methyl-N '-nitro-N-nitrosoguanidine 
(MNNG) (3, 8, 13, 19). However, the limited number of pa- 
tient-derived cell lines used in those studies (n = 4-7), the appli- 
cation of long-term cell culture instead of using freshly isolated 
cells and some conflicting evidence reported later (10,11) made 
it necessary to confirm and extend these early observations. 
Our present set of data on large groups of AD patients and 
matched control subjects definitely confirm and considerably ex- 
tend earlier findings of a DNA repair defect in familiar AD 
(8,13). These earlier determinations have not been made on 
freshly isolated cells from AD patients, but on a small number 
of cell lines derived from AD patients. The use of freshly iso- 
lated cells in the present study refutes the possibility that ob- 
served differences among individuals within a group or between 
different groups are an artefact of culture. However, it should 
be realized that in our study no histopathological examination 
has as yet confirmed the clinical diagnosis of AD. This could 
partly explain the large individual variation observed in the 
groups. 
In a previous study, we have used the excision repair inhibi- 
tor 1-[3-arabino-furanosylcytosine to provide evidence that the 
most likely type of defect responsible for the low ENU-induced 
SSB repair observed in some individuals is a lesion-specific step 
in excision repair, e.g., glycosylation (1). In this regard it should 
be noted that different alkylating agents induce a different spec- 
trum of DNA lesions, the removal of which may require differ- 
ent repair pathways and possibly different glycosylases. Therefore, 
the previously reported DNA repair defect in cells from sporadic 
AD patients, detected after treatment with MMS (19), is not 
necessarily in conflict with our present results but could be the 
consequence of the different alkylating agents used. 
Whether defective DNA repair is related to or closely linked 
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to the etiology and/or pathophysiology of familial AD is not 
clear at this time. A diminished DNA repair in familial but not 
in sporadic AD could either be a consequence of a different 
pathogenesis of familial AD or could represent a genetic defect 
only present in familial AD. Medical treatment was similar for 
familial and sporadic AD patients, Therefore, the decrease in 
DNA repair cannot be ascribed to differences in medication. Al- 
though the repair of ENU-induced DNA lesions in sporadic AD 
patients is quantitatively similar to that observed in normal con- 
trol subjects, this does not necessarily exclude differences in 
other pathways, or qualitative differences in, for example, the 
fidelity of DNA repair processes. Both a decreased rate of re- 
pair and/or a lower fidelity of DNA repair in nondividing cells, 
such as neurons, could have adverse ffects on the expression of 
genes important for neuronal function and survival. 
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